(NASDAQ: LBRX) Lb Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast earnings growth rate of 11.39%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 31.51%.
Lb Pharmaceuticals's earnings in 2026 is -$85,685,000.On average, 11 Wall Street analysts forecast LBRX's earnings for 2026 to be -$187,432,259, with the lowest LBRX earnings forecast at -$195,690,607, and the highest LBRX earnings forecast at -$175,796,374. On average, 11 Wall Street analysts forecast LBRX's earnings for 2027 to be -$167,934,813, with the lowest LBRX earnings forecast at -$198,535,867, and the highest LBRX earnings forecast at -$127,359,223.
In 2028, LBRX is forecast to generate -$154,979,529 in earnings, with the lowest earnings forecast at -$231,414,418 and the highest earnings forecast at -$101,616,401.